- Home
- ATOS vs GGT Comparison
ATOS vs GGT Comparison
Compare ATOS & GGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- GGT
- Stock Information
- Founded
- ATOS 2009
- GGT 1994
- Country
- ATOS United States
- GGT United States
- Employees
- ATOS N/A
- GGT N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- GGT Trusts Except Educational Religious and Charitable
- Sector
- ATOS Health Care
- GGT Finance
- Exchange
- ATOS Nasdaq
- GGT Nasdaq
- Market Cap
- ATOS 140.9M
- GGT 136.5M
- IPO Year
- ATOS 2012
- GGT N/A
- Fundamental
- Price
- ATOS $0.96
- GGT $4.86
- Analyst Decision
- ATOS Strong Buy
- GGT
- Analyst Count
- ATOS 3
- GGT 0
- Target Price
- ATOS $7.00
- GGT N/A
- AVG Volume (30 Days)
- ATOS 952.6K
- GGT 59.7K
- Earning Date
- ATOS 11-12-2024
- GGT 01-01-0001
- Dividend Yield
- ATOS N/A
- GGT 15.56%
- EPS Growth
- ATOS N/A
- GGT N/A
- EPS
- ATOS N/A
- GGT 0.83
- Revenue
- ATOS N/A
- GGT N/A
- Revenue This Year
- ATOS N/A
- GGT N/A
- Revenue Next Year
- ATOS N/A
- GGT N/A
- P/E Ratio
- ATOS N/A
- GGT $6.90
- Revenue Growth
- ATOS N/A
- GGT N/A
- 52 Week Low
- ATOS $0.73
- GGT $4.32
- 52 Week High
- ATOS $2.31
- GGT $7.00
- Technical
- Relative Strength Index (RSI)
- ATOS 24.57
- GGT 49.92
- Support Level
- ATOS $1.17
- GGT $4.61
- Resistance Level
- ATOS $1.30
- GGT $5.12
- Average True Range (ATR)
- ATOS 0.08
- GGT 0.08
- MACD
- ATOS -0.02
- GGT -0.04
- Stochastic Oscillator
- ATOS 1.09
- GGT 48.08
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About GGT Gabelli Multi-Media Trust Inc. (The)
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.